Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667901 · ClinicalTrials.gov registry record · Phase 1
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
A Phase 1 study, sponsored by University of Medicine and Dentistry of New Jersey.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00667901: Clinical Trial Phase 1 study, sponsored by University of Medicine and Dentistry of New Jersey.
NCT00667901 is a Phase 1 study that was terminated before completion, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00667901, a Phase 1 study, was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This early phase I trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that can be removed by surgery.
Interventions
- GENETIC protein expression analysis
- OTHER immunohistochemistry staining method
- GENETIC western blotting
- GENETIC reverse transcriptase-polymerase chain reaction
- DRUG riluzole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Why NCT00667901 stopped before completion
NCT00667901 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00667901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00667901 about?
NCT00667901 is a clinical study titled "Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery". RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This early phase I trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that can be removed by surgery.
What is the current status of trial NCT00667901?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2007-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00667901?
The interventions under investigation include: protein expression analysis (GENETIC), immunohistochemistry staining method (OTHER), western blotting (GENETIC), reverse transcriptase-polymerase chain reaction (GENETIC), riluzole (DRUG).
Who is sponsoring clinical trial NCT00667901?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00667901's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia